PCSK9 Inhibitors vs Statin for Large-Artery Atherosclerotic Ischemic Stroke

The NIH registered a new prospective multicenter observational cohort study (NCT07540741) on ClinicalTrials.gov examining PCSK9 inhibitor therapy in patients with large-artery atherosclerotic ischemic stroke. The study compares evolocumab plus statin therapy against statin monotherapy across five outcome measures: early neurological improvement, lipid-lowering effect, 90-day functional outcome, recurrent cardio-cerebrovascular events, and safety outcomes.

This is a clinical trial registration with no regulatory compliance implications. Pharmaceutical manufacturers and healthcare providers involved in PCSK9 inhibitor development or clinical use may wish to monitor trial outcomes for safety and efficacy signals, but this registration imposes no new obligations or reporting requirements.